1268521-89-6 Usage
General Description
7-chloro-2-methyl-5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile is a chemical compound with the molecular formula C10H5ClF3N3. It is a pyrrolopyridine derivative with a chloro and a methyl group at specific positions on the pyrrolopyridine ring, as well as a trifluoromethyl and a carbonitrile group at other positions. 7-chloro-2-methyl-5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile is used in the pharmaceutical industry for the synthesis of potential drug candidates. It has potential applications in the development of new drugs for the treatment of various diseases, and also for research purposes in medicinal chemistry and pharmacology. However, its specific uses and properties may vary depending on the synthesis and formulation of the compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1268521-89-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,8,5,2 and 1 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1268521-89:
(9*1)+(8*2)+(7*6)+(6*8)+(5*5)+(4*2)+(3*1)+(2*8)+(1*9)=176
176 % 10 = 6
So 1268521-89-6 is a valid CAS Registry Number.
1268521-89-6Relevant articles and documents
Discovery of Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1)
Filipski, Kevin J.,Sammons, Matthew F.,Bhattacharya, Samit K.,Panteleev, Jane,Brown, Janice A.,Loria, Paula M.,Boehm, Markus,Smith, Aaron C.,Shavnya, Andre,Conn, Edward L.,Song, Kun,Weng, Yan,Facemire, Carie,Jüppner, Harald,Clerin, Valerie
, p. 440 - 445 (2018)
Sodium-phosphate cotransporter 2a, or NaPi2a (SLC34A1), is a solute-carrier (SLC) transporter located in the kidney proximal tubule that reabsorbs glomerular-filtered phosphate. Inhibition of NaPi2a may enhance urinary phosphate excretion and correct maladaptive mineral and hormonal derangements associated with increased cardiovascular risk in chronic kidney disease-mineral and bone disorder (CKD-MBD). To date, only nonselective NaPi inhibitors have been described. Herein, we detail the discovery of the first series of selective NaPi2a inhibitors, resulting from optimization of a high-throughput screening hit. The oral PK profile of inhibitor PF-06869206 (6f) in rodents allows for the exploration of the pharmacology of selective NaPi2a inhibition.
